Literature DB >> 11005559

Lymph node micrometastases do not predict relapse in stage II colon cancer.

J Tschmelitsch1, D S Klimstra, A M Cohen.   

Abstract

BACKGROUND: Over one third of patients with stage II colonic adenocarcinoma experience tumor recurrence. Because effective adjuvant therapy is now available, it is important to identify subsets of patients at higher risk for relapse who may benefit from early treatment. Immunohistochemistry has been used to detect microscopic metastases in histologically uninvolved mesenteric lymph nodes, but the prognostic significance of minimal nodal involvement has not been established.
METHODS: Hematoxylin and eosin (H&E)-stained recuts of 900 mesenteric lymph nodes from 55 patients (range, 2-47; mean, 16.4 nodes per case) with resected pT3 or pT4, N0, M0 (TNM stage II) colonic adenocarcinomas were re-examined for the presence of metastases and then stained immunohistochemically for keratin using the AE1:AE3 antibody. Twenty-seven patients did not experience recurrence of tumor within 5 years following resection (no evidence of disease [NED]); 28 patients relapsed during the same time frame. Lymph nodes from 10 patients having colonic resections for nonneoplastic disorders also were stained as controls. Keratin-positive cells and cell clusters were quantified in the lymph nodes, and comparisons were made between patients with and without tumor relapse.
RESULTS: In the relapse group, four patients had positive nodes already identified on the H&E-stained recuts and had to be excluded from further analysis. Sixteen additional patients had keratin-positive cells; thus, 16 of 24 (67%) had micrometastases. In the NED group, one patient had a positive node on H&E staining and 22 additional patients had keratin-positive cells, so 22 of 26 (84%) patients had micrometastases. In the patients who had micrometastases, there was a mean of 3.5 and 4.6 positive nodes in the relapse and NED groups, respectively, and a mean of 11.3 and 12.4 keratin-positive cells or clusters in the relapse and NED groups, respectively. No keratin-positive cells were found in the 1 to 21 (mean, 9.1) nodes per case studied in the control patients.
CONCLUSIONS: Micrometastases to histologically uninvolved mesenteric lymph nodes commonly are detected in patients with pT3 or pT4 colonic adenocarcinomas on recuts stained immunohistochemically for keratin. Nodal micrometastases detected by immunohistochemical staining are not useful for identifying stage II patients at higher risk for relapse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005559     DOI: 10.1007/bf02725340

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Adjuvant treatment of early colon cancer with micrometastases: results of a national survey.

Authors:  Scott S Short; Alexander Stojadinovic; Aviram Nissan; Zev Wainberg; Deepti Dhall; Kathy Yao; Anton Bilchik
Journal:  J Surg Oncol       Date:  2012-02-03       Impact factor: 3.454

Review 2.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 3.  Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature.

Authors:  Daniel G Nicastri; John T Doucette; Tony E Godfrey; Steven J Hughes
Journal:  J Mol Diagn       Date:  2007-10-04       Impact factor: 5.568

Review 4.  Clinical impact of minimal cancer cell detection in various colorectal cancer specimens.

Authors:  Kazuhiko Yoshimatsu; Hajime Yokomizo; Yoshihiko Naritaka
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Tumor micrometastases in mesorectal lymph nodes and their clinical significance in patients with rectal caner.

Authors:  Yang-Chun Zheng; Yu-Ying Tang; Zong-Guang Zhou; Li Li; Tian-Cai Wang; Yi-Ling Deng; Dai-Yun Chen; Wei-Ping Liu
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

6.  Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size.

Authors:  Carsten T Viehl; Christian T Hamel; Walter R Marti; Ulrich Guller; Lukas Eisner; Uz Stammberger; Luigi Terracciano; Hans P Spichtin; Felix Harder; Markus Zuber
Journal:  World J Surg       Date:  2003-11-06       Impact factor: 3.352

7.  Sentinel node staging of resectable colon cancer: results of a multicenter study.

Authors:  Monica Bertagnolli; Brent Miedema; Mark Redston; Jeannette Dowell; Donna Niedzwiecki; James Fleshman; Jiri Bem; Robert Mayer; Michael Zinner; Carolyn Compton
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

8.  [Optimization of staging in colon cancer using sentinel lymph node biopsy].

Authors:  A Bembenek; U Schneider; S Gretschel; C Ulmer; P M Schlag
Journal:  Chirurg       Date:  2005-01       Impact factor: 0.955

Review 9.  Lymphatic drainage of the liver and its implications in the management of colorectal cancer liver metastases.

Authors:  Renato Micelli Lupinacci; François Paye; Fabricio Ferreira Coelho; Jaime Arthur Pirolla Kruger; Paulo Herman
Journal:  Updates Surg       Date:  2014-08-29

10.  Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer.

Authors:  Robert Rosenberg; Jan Friederichs; Ralf Gertler; Axel Hoos; James Mueller; Jorg Nahrig; Hjalmar Nekarda; Joerg-Ruediger Siewert
Journal:  Int J Colorectal Dis       Date:  2004-01-10       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.